| Literature DB >> 30777045 |
C Lan1,2, J Li1,2, X Huang1,2, A Heindl3,4,5, Y Wang1,2, S Yan6,2, Y Yuan7,8,9.
Abstract
BACKGROUND: Identifying high-risk patients for platinum resistance is critical for improving clinical management of ovarian cancer. We aimed to use automated image analysis of hematoxylin & eosin (H&E) stained sections to identify the association between microenvironmental composition and platinum-resistant recurrent ovarian cancer.Entities:
Keywords: Automated image analysis; Ovarian cancer; Platinum resistant relapse; Stromal cell ratio
Mesh:
Substances:
Year: 2019 PMID: 30777045 PMCID: PMC6380057 DOI: 10.1186/s12885-019-5343-8
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Clinicopathologic characteristics for patients with recurrent ovarian cancer
| Characteristics | Platinum-sensitive recurrence ( | Platinum-resistant recurrence ( | |
|---|---|---|---|
| Age | 0.395 | ||
| ≤ 60 years | 40 (71.4) | 16 (28.6) | |
| > 60 years | 9 (60.0) | 6 (40.0) | |
| Residual disease | 0.783 | ||
| ≤ 1 cm | 25 (67.6) | 12 (32.4) | |
| > 1 cm | 24 (70.6) | 10 (29.4) | |
| FIGO stage | 0.115 | ||
| Stage III | 46 (71.9) | 18 (28.1) | |
| Stage IV | 3 (42.9) | 4 (57.1) | |
| Histologic types | 0.946 | ||
| High-grade serous carcinoma | 44 (69.8) | 19 (30.2) | |
| Low-grade serous carcinoma | 2 (66.7) | 1 (33.3) | |
| Mucinous | 1 (50.0) | 1 (50.0) | |
| Endometrioid | 2 (66.7) | 1 (33.3) | |
| Normalization of CA125 level after 3 cycles of chemotherapy | < 0.001 | ||
| Yes | 43 (82.7) | 9 (17.3) | |
| No | 6 (31.6) | 13 (68.4) | |
Fig. 1The association between microenvironmental composition (a-c stromal cell, tumor cell and lymphocyte ratio assessed by automated image analysis, d-f stromal cell, tumor cell and lymphocyte ratio assessed by pathologist’s scores) and relapse types of ovarian cancer
Logistic regression analyses on risk factors for platinum-resistant recurrent ovarian cancer
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Odds ratio (95%CI) | Odds ratio (95%CI) | |||
| Age | ||||
| ≤ 60 years | 1 | 1 | ||
| > 60 years | 1.67 (0.51–5.45) | 0.398 | 2.05 (0.33–12.88) | 0.446 |
| Residual disease | ||||
| ≤ 1 cm | 1 | 1 | ||
| > 1 cm | 0.87 (0.32–2.38) | 0.783 | 0.38 (0.07–2.00) | 0.251 |
| FIGO stage | ||||
| Stage III | 1 | 1 | ||
| Stage IV | 3.41 (0.69–16.76) | 0.131 | 7.52 (0.46–121.94) | 0.156 |
| Histologic types | ||||
| High-grade serous carcinoma | 1 | 1 | ||
| Others | 1.39 (0.30–6.41) | 0.673 | 2.05 (0.24–17.49) | 0.512 |
| Normalization of CA125 level after 3 cycles of chemotherapy | ||||
| Yes | 1 | 1 | ||
| No | 16.00 (4.66–54.91) | < 0.001 | 18.06 (3.69–88.38) | < 0.001 |
| Stromal cell ratio | ||||
| Low | 1 | 1 | ||
| High | 13.88 (3.92–49.11) | < 0.001 | 14.69 (2.79–77.35) | 0.002 |
Predictive models for platinum-resistant recurrent ovarian cancer
| Model I | Model II | Model III | |
|---|---|---|---|
| Sensitivity | 81.82% | 72.70% | 95.50% |
| Specificity | 75.51% | 85.70% | 65.30% |
| Positive predictive value | 60.00% | 69.57% | 55.26% |
| Negative predictive value | 90.24% | 87.50% | 96.97% |
| AIC | 70.60 | 68.44 | 56.49 |
| Youden index | 0.57 | 0.58 | 0.61 |
| AUC | 0.78 | 0.79 | 0.89 |
| 95% CI for AUC | 0.66–0.89 | 0.67–0.92 | 0.81–0.97 |
A. Stromal cell ratio based on automated image analysis
B. Normalization of CA125 level after 3 cycles of chemotherapy
Model I: A
Model II: B
Model III: A + B
AIC Akaike information criterion
AUC Area under curve
Fig. 2ROC curves of predictive models for platinum resistant relapse of ovarian cancer. (i) Stromal cell ratio based on automated image analysis (ii) Normalization of CA125 level after 3 cycles of chemotherapy